| abstract |
One aspect of the present invention is an antisense strand complementary to a target gene; a sense strand complementary to the antisense strand; and one or more lipophilic monomers containing one or more lipophilic moieties conjugated at one or more positions of at least one strand, optionally via a linker or carrier. Another aspect of the invention relates to a method of gene silencing, comprising administering to a cell or subject in need thereof a therapeutically effective amount of a lipophilic monomer-conjugated compound. |